Tim Boreham

LTR Pharma has added testosterone to its erectile dysfunction reportoire, via an exclusive agreement with Marius Pharmaceuticals Inc.

Investors are awaiting late-stage clinical results that are likely to make or break the biotechs in question.

This reporting season, investors have rewarded companies on the comeback trail with a sniff of improved performance – or merely a promise of such.

Amid a range of external and domestic influences, this reporting season is hard to predict. The only certainty is plenty of surprises.

Radiopharm Theranostics is capitalising on today's two promising cancer imaging trial updates to replenish its coffers.

Broker UBS warns that rival Envoy Medical may steal a march on Cochlear in the emerging Totally Implantable Cochlear Implant (TICI) sector.

After a double whammy blow, Cynata is “actively reviewing” alternative uses for its Cymerus platform technology. After a double whammy blow, Cynata is “actively reviewing” alternative uses for its Cymerus platform technology.

A leading global small caps manager says the art of stock picking lies in avoiding the herd - and looking management in the eyes. 

Drug developers have delivered promising news in the fields of cancer, cardioprotection, delirium and motor system atrophy.

Artrya’s FDA-cleared AI heart imaging tools are now reimbursable in the US, targeting one of healthcare’s deadliest blind spots: hidden heart disease.